ACC.12 late-breaking trials cover gamut of clinical advances

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon
David Holmes - 33.48 Kb
David R. Holmes, Jr., MD Source: American College of Cardiology (ACC)

The American College of Cardiology’s (ACC) 61st annual scientific sessions, March 24-27 in Chicago, is shaping up to be a blockbuster event, according to ACC President David R. Holmes, Jr., MD. “This meeting will be tremendous,” he said in a press briefing. “We stand on the cusp of the science and education that will be highlighted in Chicago.”

The Cardiovascular Business editorial team will provide comprehensive coverage of the event, which offers more than a dozen late-breaking clinical trials that not only cover treatments ranging from therapeutics to imaging, but also incorporate a large body of data from international studies. 

“This is an amazing lineup of late-breaking clinical trials that are aimed at broad and different ideas, patient care strategies and patient groups,” Holmes said. The late-breaking trials and the date they will be presented are provided below.

Saturday, March 24
FOCUS Study: A randomized clinical trial to study the efficacy of bone marrow cells to improve indices of heart function in patients with coronary disease and reduced heart function. In the study, autologous bone marrow mononuclear cells were harvested from patients with ischemic heart failure and then re-injected into their functioning myocardium. The study is supported by the National Institutes of Health’s Cardiovascular Cell Therapy Research Network.

TIMI 50 Trial: A double-blind prospective clinical trial to assess whether vorapaxar (Merck), a novel antiplatelet agent, added to standard care helps reduce adverse cardiovascular outcomes such as death, MI or stroke in patients with chronic ischemic heart disease. Vorapaxar has been found to be beneficial in the acute setting.

Sunday, March 25
CPORT-E Trial: A randomized trial designed to evaluate the safety and efficacy of performing elective PCI in hospitals without cardiac surgery backup compared with hospitals with onsite cardiac surgery available if an emergency develops during the procedure. The final nine-month results will be presented.

INFUSE-AMI trial: A multicenter, prospective, randomized evaluation of the efficacy of the combination abciximab (ReoPro, Eli Lilly), an intravenous antiplatelet agent, with the use of aspiration thrombectomy at the time of anterior STEMI in patients undergoing primary PCI.

HOST-ASSURE trial: A randomized trial designed to compare two antiplatelet strategies—adding cilostazol (Pletal, Otsuka Pharmaceutical) in combination with aspirin versus doubling the dose of clopidogrel (Plavix, Bristol-Myers Squibb/Sanofi-Aventis) in combination with aspirin—after patients receive PCI. The trial is based in Seoul, South Korea, where cilostazol is frequently used to prevent stent thrombosis.

BRIDGE-ACS trial: A Brazilian registry study of an intervention designed to increase the frequency that patients receive evidence-based medications and treatments following presentation of ACS.

Monday, March 26
CORONARY trial: A large, international trial designed to compare the risks and benefits of off-pump CABG to on-pump CABG and to determine if one is better than the other. It is the largest comparison trial of the two techniques, based on data from nearly 5,000 patients at 80 centers across 20 countries.

ACRIN-PA trial: A multicenter, randomized controlled study of the American College of Radiology Imaging Network (ACRIN) to compare coronary CT angiography (CCTA) versus standard care of low-risk patients in emergency departments who present with potential ACS. In the study, patients were randomized to either a traditional “rule out” care group or a CCTA group to determine whether CCTA can be safely used to discharge low-risk patients to home from the emergency department.

EINSTEIN PE trial: An investigation of the use of oral, direct Factor Xa inhibitor rivaroxaban (Xarelto, Janssen Research & Development) compared with standard care in the treatment of patients with pulmonary embolism.

PARTNER trial: The two-year results on Cohort A of the PARTNER trial, focusing on the clinical and echocardiographic outcomes after transcatheter versus surgical aortic valve replacement. The Partner A cohort consists of high-risk patients. In this study, half of the high-risk patients were randomized to transcatheter and half to standard aortic valve replacement surgery.

STAMPEDE trial: A three-armed randomized study to compare two types of bariatric surgery for the treatment